Tysabri

Monday, 15 November 2021

Latest News for: tysabri

Edit

Perrigo tax bill over Tysabri sale falls to less than €1bn

The Irish Times 13 Jul 2021

The disputed tax bill relates to the sale by Elan of its intellectual property interests in multiple sclerosis drug Tysabri in 2013 to Biogen for an up-front payment of $3.25 billion and a share of future royalties ... Among the issues that drove the downward revision was the failure of Tysabri to meet certain sales targets after its sale.

Edit

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

Pharmiweb 29 Apr 2021

Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of administration of TYSABRI® (natalizumab) to treat relapsing multiple sclerosis (MS) ... About TYSABRI® (natalizumab). TYSABRI is a well-established ...

Edit

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab) (Biogen Inc)

Public Technologies 29 Apr 2021

Edit

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat ...

Nasdaq Globe Newswire 07 Apr 2021

BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI® ...

Edit

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis (Biogen Inc)

Public Technologies 07 Apr 2021

BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI® (natalizumab) to treat relapsing-remitting multiple sclerosis (MS) ... The SC and IV formulations of TYSABRI are dosed 300 mg, every four weeks (Q4W) by a healthcare provider ... About TYSABRI® (natalizumab).

Edit

Tysabri Market Report Insights, Product Outlook, Forecast from 2021-2026

MENA FN 27 Jan 2021

(MENAFN - Ameliorate Solutions) Global Tysabri Market trends analysis report 2021, the future of the industries is predicted on the basis of the curr... .

Edit

Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months

PR Newswire 07 Oct 2019

Conversely, Teva's Copaxone and Biogen's Tysabri and Avonex have all experienced significant share declines ... Only 11 of the 1,266 EU patients, captured in the Spherix audit, had recently switched from Lemtrada with those patients typically moving to Ocrevus or Tysabri due to, not unsurprisingly, safety concerns.

Edit

Novartis' Gilenya, Sanofi's Aubagio, Biogen's Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement

PR Newswire 13 Aug 2019

Data collected from 1,266 multiple sclerosis (MS) patients recently switched to a new DMT within the three months prior to fielding reveal Novartis' Gilenya, Sanofi's Aubagio, and Biogen's Tysabri and Tecfidera as the switch segment leaders in Europe.